Abbott Laboratories sees continued double-digit growth, contributing to outperformance

From Yahoo Finance: 2025-05-07 09:45:00

Mairs & Power released their first quarter 2025 investor letter, noting a record high in February before a March dip due to tariff uncertainty. The fund ended the quarter up 0.04%, outperforming benchmark indexes and the Morningstar Moderate Allocation peer group. Check out their top five holdings for 2025 picks.

Abbott Laboratories (NYSE: ABT) was highlighted in Mairs & Power Balanced Fund’s Q1 2025 letter. The stock saw a one-month return of 4.74% and a 26.80% increase over the last 52 weeks. On May 6, 2025, Abbott Laboratories closed at $133.06 per share with a market cap of $231.503 billion.

Mairs & Power Balanced Fund reported Abbott Laboratories contributed to their outperformance, noting the company’s sixth consecutive quarter of double-digit organic growth. With a positive trajectory, Abbott Laboratories remains a long-term portfolio holding appreciated by the market.

Abbott Laboratories (NYSE: ABT) remains a popular stock among hedge funds, with 66 hedge fund portfolios holding it at the end of the fourth quarter. While the stock holds potential, AI stocks are believed to offer greater returns in a shorter timeframe. Explore our report on the cheapest AI stock for promising investment opportunities.

Read more: Abbott Laboratories (ABT) Continued Sixth Straight Quarter of Double-Digit Gains